{
  "question_id": "hmcor25029",
  "category": "hm",
  "educational_objective": "Treat hereditary hemochromatosis.",
  "metadata": {
    "care_types": [],
    "patient_types": [],
    "high_value_care": false,
    "question_updated": "12/25/2025"
  },
  "question_text": "A 68-year-old man is evaluated for progressive fatigue. Medical history is unremarkable, and he takes no medications. Family history is significant for heart failure in his father at age 65 years.On physical examination, vital signs are normal. The patient has tanned skin. The remainder of the examination is normal.Laboratory studies:Hemoglobin16 g/dL (160 g/L)Albumin4 g/dL (40 g/L)Alanine aminotransferase92 U/LHAspartate aminotransferase73 U/LHBilirubin, total0.9 mg/dL (15.4 μmol/L) Glucose, fasting210 mg/dL (11.6 mmol/L)HFerritin750 ng/mL (750 µg/L)HTransferrin saturation52%HINR1.1Homozygous C282Y variant of the HFE gene is discovered on genetic testing.",
  "question_stem": "Which of the following is the most appropriate management?",
  "options": [
    {
      "letter": "A",
      "text": "Iron chelation therapy",
      "peer_percentage": 0
    },
    {
      "letter": "B",
      "text": "Liver biopsy",
      "peer_percentage": 0
    },
    {
      "letter": "C",
      "text": "Phlebotomy",
      "peer_percentage": 0
    },
    {
      "letter": "D",
      "text": "Expectant management",
      "peer_percentage": 0
    }
  ],
  "user_performance": {
    "user_answer": null,
    "correct_answer": "C",
    "result": null,
    "time_taken": null
  },
  "critique": "Therapeutic phlebotomy (Option C) is the most appropriate treatment for this patient with hereditary hemochromatosis (HH). The diagnosis of HH is established through genetic testing. A dominant form of HH involves alterations in the HFE gene, with homozygosity for the C282Y variant accounting for approximately 90% of patients with hemochromatosis. In patients with established HH, phlebotomy is the mainstay of treatment to remove excess iron and prevent end-organ damage. Recommended phlebotomy frequency and goal ferritin level vary between guidelines. The American College of Gastroenterology (ACG) recommends treatment in patients with homozygous C282Y variants who have a transferrin saturation of 45% or greater along with a serum ferritin level greater than 300 ng/mL (300 µg/L) in men and greater than 200 ng/mL (200 µg/L) in women. Other sources recommend observation for ferritin levels less than 500 ng/mL (500 µg/L). This patient has a homozygous C282Y variant and evidence of end-organ damage with diabetes mellitus, elevated aminotransferase levels, and skin hyperpigmentation. Therapeutic phlebotomy is indicated.Iron chelation (Option A) is typically reserved for patients with iron overload who cannot tolerate phlebotomy because of chronic anemia from inherited or acquired disorders of erythropoiesis. Therapeutic phlebotomy is preferred for managing iron overload in HH. This patient has a normal hemoglobin level and no contraindications to phlebotomy, so iron chelation is not appropriate.The use of liver biopsy (Option B) to quantify the degree of iron overload in HH has mostly been replaced by T2-weighted MRI. Liver biopsy can be useful in establishing the extent of liver disease and the presence of fibrosis or cirrhosis, although this patient's normal albumin, bilirubin, and INR levels suggest well-preserved hepatic synthetic and metabolic function. Liver ultrasonography with elastography to estimate the extent of fibrosis would also be preferable to biopsy in the assessment of fibrosis and cirrhosis.Persons with a homozygous HFE variant without evidence of organ damage or elevated iron indices do not require immediate intervention and can be monitored for indications for treatment (Option D). This patient has abnormal aminotransferase levels, skin hyperpigmentation, probably diabetes, and a significantly elevated serum ferritin level, so therapeutic phlebotomy is indicated.",
  "key_points": [
    "Patients with hereditary hemochromatosis (HH) who have an elevated serum ferritin level or end-organ damage, including liver disease, cardiac involvement, or arthropathy, should be treated with therapeutic phlebotomy.",
    "In patients with HH, the use of liver biopsy to quantify the degree of iron overload has mostly been replaced by T2-weighted MRI."
  ],
  "references": "Cabrera E, Crespo G, VanWagner LB. Diagnosis and management of hereditary hemochromatosis. JAMA. 2022;328:1862-1863. PMID: 36346422 doi:10.1001/jama.2022.17727",
  "related_content": {
    "syllabus": [
      "hmsec24005_24001"
    ],
    "learning_plan_topic": ""
  },
  "media": {
    "tables": [],
    "images": [],
    "svgs": [],
    "videos": []
  },
  "extracted_at": "2025-12-25T11:28:09.047911-06:00"
}